Pure Global
NCT06267846

A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1070770 in Adults With Major Depressive Disorder
Neurocrine Biosciences·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Major Depressive Disorder
Drug/Device/Intervention
NBI-1070770
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Neurocrine Biosciences
Location
Rogers,Lemon Grove,Long Beach,Hollywood,Gaithersburg, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Mar 01, 2024
End date
Dec 01, 2025
Enrollment
72 participants
Primary outcome

Change in Total Montgomery-Åsberg Depression Rating Scale (MADRS) Score from Baseline to Day 5

Summary

To evaluate the efficacy, safety, and tolerability of NBI-1070770 compared to placebo on
 improving symptoms of depression in participants with major depressive disorder (MDD).

ICD-10 classifications
Recurrent depressive disorderRecurrent depressive disorder, unspecifiedDepressive conduct disorderOther recurrent depressive disordersRecurrent depressive disorder, current episode moderate
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06267846
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06267846 through Pure Global AI's free database. This Phase 2 trial is sponsored by Neurocrine Biosciences and is currently Recruiting. The study focuses on Major Depressive Disorder. Target enrollment is 72 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.